IFNα1(69–189)R9 was tested for its ability to therapeutically treat SJL/J mice for experimental allergic encephalomyelitis (EAE), a mouse model of MS, without the toxicity associated with IFNβ treatment. Here, IFNA1 is linked to myeloid sarcoma.